DESMOPRESSIN ADVZ (Boucher & Muir Pty Ltd)
Product name
DESMOPRESSIN ADVZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
127 (255 working days)
Active ingredients
desmopressin acetate
Registration type
New generic medicine
Indication
Desmopressin ADVZ is indicated for the treatment of;
- cranial diabetes insipidus
- primary nocturnal enuresis in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm or in whom an enuresis alarm is contraindicated or inappropriate.